MED12 and CDK8/19 Modulate Androgen Receptor Activity and Enzalutamide Response in Prostate Cancer

Abstract Prostate cancer progression is driven by androgen receptor (AR) activity, which is a target for therapeutic approaches. Enzalutamide is an AR inhibitor that prolongs the survival of patients with advanced prostate cancer. However, resistance mechanisms arise and impair its efficacy. One of...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Endocrinology (Philadelphia) 2024-08, Vol.165 (10)
Hauptverfasser:	Andolfi, Chiara, Bartolini, Caterina, Morales, Elisa, Gündoğdu, Büşra, Puhr, Martin, Guzman, Juan, Wach, Sven, Taubert, Helge, Aigner, Achim, Eder, Iris E, Handle, Florian, Culig, Zoran
Format:	Artikel
Sprache:	eng
Schlagworte:	Alternative splicing Androgen receptors Androgens Benzamides c-Myc protein Cell Line, Tumor Cell proliferation Cell Proliferation - drug effects Cyclin-dependent kinase Cyclin-Dependent Kinase 8 - genetics Cyclin-Dependent Kinase 8 - metabolism Cyclin-dependent kinases Cyclin-Dependent Kinases - antagonists & inhibitors Cyclin-Dependent Kinases - genetics Cyclin-Dependent Kinases - metabolism Drug Resistance, Neoplasm - drug effects Drug Resistance, Neoplasm - genetics Gene expression Gene Expression Regulation, Neoplastic - drug effects Humans Kinases Male Mediator Complex - genetics Mediator Complex - metabolism Myc protein Nitriles Phenylthiohydantoin - pharmacology Prostate cancer Prostate-specific antigen Prostatic Neoplasms - drug therapy Prostatic Neoplasms - genetics Prostatic Neoplasms - metabolism Prostatic Neoplasms - pathology Proteins Receptors Receptors, Androgen - genetics Receptors, Androgen - metabolism Secretion Spheroids Tumor cell lines
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!